文献速递其他结缔组织病

干燥综合征与抗cN1A抗体在肌炎患者中的意义

Significance of Sjögren's syndrome and anti-cN1A antibody in myositis patients.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

单中心回顾性分析99例特发性炎性肌病(EULAR/ACR 2017标准)患者,其中34例合并干燥综合征(SS)。合并SS者包涵体肌炎(IBM)患病率显著高于无SS者(24% vs 6%,P=0.020),抗cN1A抗体阳性率亦显著升高(38% vs 6%,P=0.0005),且与IBM诊断独立相关。抗cN1A对IBM的特异性在无SS组为0.96,合并SS组降至0.70。

要点

  • 肌炎合并SS者IBM患病率显著高于无SS者(24% vs 6%,P=0.020)。
  • 抗cN1A在合并SS的肌炎患者中更常见(38% vs 6%,P=0.0005),独立于IBM。
  • 抗cN1A对IBM特异性在合并SS时降至0.70,解读需谨慎。

核心结论

  • 在肌炎患者中,干燥综合征与IBM及抗cN1A抗体相关,且该关联独立于IBM诊断。
  • 合并SS时抗cN1A对IBM的特异性有限。

研究设计与样本

  • 单中心累积数据分析,纳入99例符合EULAR/ACR 2017标准的肌炎患者,均筛查SS(ACR/EULAR 2016标准),中位随访6年(范围1.0–37.5年)。
  • 比较34例合并SS的肌炎患者与65例无SS的肌炎患者。

主要发现

  • IBM在合并SS组占24%,无SS组占6%(P=0.020)。
  • 抗cN1A在合并SS组占38%,无SS组占6%(P=0.0005),多因素分析P=0.02。
  • 无论是否合并SS,IBM患者均对治疗无应答。
  • 抗cN1A对IBM的特异性在无SS组为0.96(95%CI 0.87, 0.99),合并SS组为0.70(95%CI 0.48, 0.85)。

关键数值与推荐

  • 肌炎诊断采用EULAR/ACR 2017标准,SS诊断采用ACR/EULAR 2016标准。
  • 抗cN1A对IBM特异性:无SS组0.96(95%CI 0.87, 0.99),合并SS组0.70(95%CI 0.48, 0.85)。

临床怎么用

  • 对肌炎合并SS患者应警惕IBM可能,抗cN1A阳性不能单独确诊IBM。
  • IBM对治疗无应答,无论是否合并SS。

局限性

  • 单中心回顾性设计,样本量99例,随访时间跨度大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We recently recorded a high prevalence of inclusion body myositis (IBM) in patients with Sjögren's syndrome (SS). Whether myositis patients with SS differ from myositis patients without SS in terms of the characteristics of the myositis is currently unknown. Anti-cytosolic 5'-nucleotidase 1 A (cN1A) has recently been proposed as a biomarker for IBM but is also frequent in SS. Whether anti-cN1A is independently associated with IBM is still an open question. We aimed to assess the significance of SS and anti-cN1A in myositis patients. METHODS: Cumulative data on all myositis patients (EULAR/ACR 2017 criteria) screened for SS (ACR/EULAR 2016 criteria) in a single centre were analysed. Ninety-nine patients were included, covering the whole spectrum of EULAR/ACR 2017 myositis subgroups and with a median follow-up of 6 years (range 1.0-37.5). The 34 myositis patients with SS (myositis/SS+) were compared with the 65 myositis patients without SS (myositis/SS-). RESULTS: . IBM was present in 24% of the myositis/SS+ patients vs 6% of the myositis/SS- group (P = 0.020). None of the IBM patients responded to treatment, whether they had SS or not. Anti-cN1A was more frequent in myositis/SS+ patients (38% vs 6%, P = 0.0005), independently of the higher prevalence of IBM in this group (multivariate P value: 0.02). Anti-cN1A antibody specificity for IBM was 0.96 (95% CI: 0.87, 0.99) in the myositis/SS- group but dropped to 0.70 (95% CI: 0.48, 0.85) in the myositis/SS+ group. INTERPRETATION: In myositis patients, SS is associated with IBM and with anti-cN1A antibodies, independently of the IBM diagnosis. As a consequence, anti-cN1A has limited specificity for IBM in myositis patients with SS.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Levy D, Nespola B, Giannini M, et al. Significance of Sjögren's syndrome and anti-cN1A antibody in myositis patients. Rheumatology (Oxford). 2022. PMID: 33974078. doi:10.1093/rheumatology/keab423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。